[go: up one dir, main page]

WO2000021534A1 - Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine - Google Patents

Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine Download PDF

Info

Publication number
WO2000021534A1
WO2000021534A1 PCT/GB1999/003398 GB9903398W WO0021534A1 WO 2000021534 A1 WO2000021534 A1 WO 2000021534A1 GB 9903398 W GB9903398 W GB 9903398W WO 0021534 A1 WO0021534 A1 WO 0021534A1
Authority
WO
WIPO (PCT)
Prior art keywords
domperidone
migraine
ibuprofen
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/003398
Other languages
English (en)
Inventor
Stephen G. Mann
Gudola Schirmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woelm Pharma GmbH and Co
Organon Pharma UK Ltd
Original Assignee
Woelm Pharma GmbH and Co
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woelm Pharma GmbH and Co, Merck Sharp and Dohme Ltd filed Critical Woelm Pharma GmbH and Co
Priority to EP99949222A priority Critical patent/EP1121124A1/fr
Priority to AU62197/99A priority patent/AU6219799A/en
Priority to CA002347192A priority patent/CA2347192A1/fr
Publication of WO2000021534A1 publication Critical patent/WO2000021534A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Definitions

  • the present invention relates to a pharmaceutical composition comprising a combination of active ingredients. More particularly, the invention concerns a pharmaceutical formulation comprising ibuprofen lysinate in combination with domperidone or a salt thereof, for use in the control of migraine, and in particular migraine-associated nausea and vomiting, and of headache with nausea following overindulgence.
  • Migraine is a recurrent, often familial, symptom complex of periodic attacks of vascular headache, which is frequently associated with nausea and vomiting. Migraine affects approximately 17% of adult women and 6% of adult men (Stewart et al, Neurology, 1994, 44 (suppl. 4), 517-523).
  • Ibuprofen, or ( ⁇ )-2-(p-isobutylphenyl)propionic acid is a well-known non-steroidal anti-inflammatory drug (NSAID) of the formula
  • the compound is widely prescribed for its analgesic and anti-pyretic activity. It is also available as a low dose over-the-counter product to be used orally for the treatment of minor aches and pains, and as a topically applied gel for the treatment of muscular sprains and strains.
  • the lysine salt of ibuprofen has been developed in order to confer water solubility upon the compound, primarily to assist in the development of an injectable form of ibuprofen.
  • UK Patent Specification No. 1,471,910 published 27th April 1977 describes the lysine salt of ibuprofen and its formulation as injectable solutions, tabloids, freeze-dried in vials on a mannitol support, ampoules, capsules, suppositories and ointments for local applications.
  • Clinical experience suggests that, amongst all the available modes of administration, patients find that orally administered medicaments are the simplest to use.
  • the efficacy of drugs given orally to relieve migraine attacks is not always reliable as gastrointestinal motility is inhibited even in the earliest stages of an attack, and there is always a risk of nausea during the attack culminating in vomiting.
  • Domperidone has an antinauseant effect through an action at the chemoreceptor trigger zone. It also has a gastric prokinetic effect through an action on gut dopaminergic receptors. Gastric stasis is a feature of migraine attacks and can also contribute to nausea experienced after an excess of alcohol consumption. It is also possible that domperidone will increase the absorption of the ibuprofen lysine through counteracting gastric stasis. Ibuprofen lysinate provides rapid absorption of racemic ibuprofen because the lysine salt is very soluble. Thus this compound is particularly well suited to treatment of headache in migraine and overindulgence where drug absorption may be compromised.
  • the present invention accordingly provides a method for the treatment and/or prevention of migraine which comprises administering to a patient in need of such treatment, simultaneously, separately or sequentially, an effective amount of a combination of ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method for the treatment and/or prevention of migraine-associated nausea and vomiting or of headache with nausea following overindulgence, which comprises administering to a patient in need of such treatment, simultaneously, separately or sequentially, an effective amount of a combination of ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof.
  • the present invention also provides the use of a combination of ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prevention of migraine.
  • the present invention further provides the use of a combination of ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prevention of migraine-associated nausea and vomiting or of headache with nausea following overindulgence.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising ibuprofen lysinate in association with domperidone or a pharmaceutically acceptable salt thereof.
  • the present invention provides a product comprising ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of migraine.
  • the present invention provides a product comprising ibuprofen lysinate and domperidone or a pharmaceutically acceptable salt thereof as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of migraine- associated nausea and vomiting or of headache with nausea following overindulge ce .
  • ibuprofen lysinate and domperidone or its pharmaceutically acceptable salt will usually be administered to a patient within a reasonable period of time, which will typically be up to about one hour apart.
  • the compounds may be in the same pharmaceutical carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers and administered simultaneously, by mixing the materials just prior to administration. They may alternatively be in different dosage forms which can be taken simultaneously, or adminstered sequentially.
  • ibuprofen is a racemic mixture.
  • the active enantiomer of ibuprofen is the S(+) enantiomer.
  • S(+) enantiomer of ibuprofen in the form of its lysine salt may be used in the same manner.
  • a particularly convenient method for the formation and resolution of ( ⁇ S)-ibuprofen-(S)-lysine is described in US Patent No. 4,994,604 (published 19th February 1991). It will also be appreciated that the lysine may exist in its racemic form or as single enantiomers.
  • the present invention refers in general to the racemate it will be appreciated that either enantiomer, such as the naturally occurring S(+) enantiomer (i.e. the laevo (L) form), may be used in the same manner.
  • the pharmaceutical composition according to the present invention majr conveniently be adapted for administration orally, rectally or parenterally.
  • the formulation may be presented in the form of tablets, pills, capsules, powders or granules; for parenteral administration, sterile parenteral solutions or suspensions may conveniently be utilised; and for rectal administration, the formulation may conveniently be in the form of suppositories.
  • the pharmaceutical compositions in accordance with the invention may be presented in the form of a kit of parts adapted for simultaneous, separate or sequential administration.
  • compositions may be formulated by conventional methods well known in the pharmaceutical art, for example as described in Remington: The Science and Practice of Pharmacy, Mack Publishing Company, 19th Edition, 1995.
  • the ibuprofen lysinate and the domperidone or its pharmaceutically acceptable salt may be presented in a ratio which is consistent with the manifestation of the desired effect.
  • the molar ratio of ibuprofen lysinate to domperidone or its pharmaceutically acceptable salt will suitably be approximately 1 to 1.
  • this ratio will be between 0.001 to 1 and 1000 to 1, and especially from 0.01:1 to 100:1.
  • ibuprofen lysinate may suitably be administered at a daily dosage of about 0.001 to 250 mg/kg, typically about 0.005 to 100 mg/kg, more particularly about 0.01 to 50 mg/kg, and especially about 0.05 to 10 mg/kg.
  • domperidone or a pharmaceutically acceptable salt thereof may suitably be administered at a daily dosage of about 0.001 to 250 mg/kg, typically about 0.005 to 100 mg/kg, more particularly about 0.01 to 50 mg/kg and especially about 0.05 to 10 mg/kg.
  • the active ingredients will typically be co-administered on a regimen of 1 to 4 times per day.
  • a sample treatment regime based upon a tablet containing 10 g of domperidone and 342 mg of ibuprofen lysinate (equivalent to 200 mg of ibuprofen) is as follows: for migraine - two tablets at the beginning of an attack with a dosage repeat after four hours if necessary up to a maximum of four dosages in twenty-four hours; for overindulgence - one or two tablets at the beginning of an attack repeated after four hours if necessary up to a maximum of eight tablets in one day.
  • Ibuprofen lysinate, compacted and Domperidone are pre-blended by hand in a pan.
  • Polyvidon K 29/32 and microcrystalline cellulose are added and hand-blended.
  • Magnesium stearate is then added and hand-blended.
  • the final mix is compressed to obtain round, flat tablets of 13 mm diameter and 409 mg weight, using a Korsch KO excenter tablet press.
  • Ibuprofen lysinate compacted 342.0 mg Domperidone 10.0 mg Polyvidon K 29/32 17.0 mg Microcrystalline Cellulose 36.0 mg Magnesium Stearate 4.0 mg
  • the microcrystalline cellulose may be Avicel PH102.
  • the magnesium stearate is generally from a vegetal source. In addition to the above ingredients about 4mg talc may be added to the mixture. Lactose fast flow may also be added.
  • the tablets may be supplied with a film coating comprising hypromellose, hydroxypropylcellulose, titanium dioxide and water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a trait à une combinaison d'ibuprofène lysine et de dompéridone pour traiter et/ou prévenir la migraine, les nausées associées à la migraine, les vomissements et les maux de tête accompagnés de nausées qui font suite à des excès.
PCT/GB1999/003398 1998-10-13 1999-10-13 Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine Ceased WO2000021534A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99949222A EP1121124A1 (fr) 1998-10-13 1999-10-13 Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine
AU62197/99A AU6219799A (en) 1998-10-13 1999-10-13 Pharmaceutical combination of ibuprofen-lysine and domperidone for treating migraine
CA002347192A CA2347192A1 (fr) 1998-10-13 1999-10-13 Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9822333.2A GB9822333D0 (en) 1998-10-13 1998-10-13 Pharmaceutical formulation
GB9822333.2 1998-10-13

Publications (1)

Publication Number Publication Date
WO2000021534A1 true WO2000021534A1 (fr) 2000-04-20

Family

ID=10840497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/003398 Ceased WO2000021534A1 (fr) 1998-10-13 1999-10-13 Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine

Country Status (5)

Country Link
EP (1) EP1121124A1 (fr)
AU (1) AU6219799A (fr)
CA (1) CA2347192A1 (fr)
GB (1) GB9822333D0 (fr)
WO (1) WO2000021534A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083119A1 (fr) * 2001-04-10 2002-10-24 The Boots Company Plc Composition pharmaceutique contenant de l'ibuprofene et de la prochlorperazine
US6991806B1 (en) 1998-08-05 2006-01-31 The Boots Company Plc Pharmaceutical compositions comprising ibuprofen and domperidone

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198889B2 (en) * 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US8715752B2 (en) 2012-09-20 2014-05-06 Quality Ip Holdings, Inc. Compositions for increasing human growth hormone levels
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034612A1 (fr) * 1997-02-06 1998-08-13 The Boots Company Plc Compositions pharmaceutiques contenant de l'ibuprofene et de la domperidone pour le traitement de la migraine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034612A1 (fr) * 1997-02-06 1998-08-13 The Boots Company Plc Compositions pharmaceutiques contenant de l'ibuprofene et de la domperidone pour le traitement de la migraine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991806B1 (en) 1998-08-05 2006-01-31 The Boots Company Plc Pharmaceutical compositions comprising ibuprofen and domperidone
WO2002083119A1 (fr) * 2001-04-10 2002-10-24 The Boots Company Plc Composition pharmaceutique contenant de l'ibuprofene et de la prochlorperazine
EP1604658A3 (fr) * 2001-04-10 2009-11-18 Reckitt Benckiser Healthcare (UK) Limited Composition pharmaceutique contenant de l'ibuprofen et de la prochlorperazine

Also Published As

Publication number Publication date
GB9822333D0 (en) 1998-12-09
CA2347192A1 (fr) 2000-04-20
EP1121124A1 (fr) 2001-08-08
AU6219799A (en) 2000-05-01

Similar Documents

Publication Publication Date Title
JP2848556B2 (ja) 非ステロイド系抗炎症剤を含むせき／かぜ複合薬
CA2182004C (fr) Comprimes enrobes de paracetamol et de domperidone
EP1274402A1 (fr) Composition pharmaceutique pour la liberation controlee de paracetamol
EP2797584B1 (fr) Combinaisons de diacéréine et d'anti-inflammatoires non stéroïdiens
AU2001260212A1 (en) Composition
US5037823A (en) Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
JP5630943B2 (ja) 複合剤組成物
US4564614A (en) Antiinflammatory methods
CA2476939A1 (fr) Combinaisons pharmaceutiques d'inhibiteurs de cox-2 et d'opiaces
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
EP1121124A1 (fr) Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine
JPH0140009B2 (fr)
US5155105A (en) Pharmaceutical methods for relief of dysmenorrhea and/or premenstrual syndrome and process
CZ79593A3 (en) Antitussive preparation
EP1242092B1 (fr) Combinaison de medicaments destinee au traitement du mal de tete comprenant mirtazapine et un medicament anti-inflammatoire non steroide
AU2001273932A1 (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
GB2336999A (en) High-dosage triclosan compositions
JP2005289906A (ja) 医薬組成物
AU2013211546B1 (en) A Medicament
JP7656339B2 (ja) 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ
JP2005289905A (ja) 医薬組成物
RU2174836C1 (ru) Фармацевтическая композиция, обладающая анальгезирующим действием
JPH07501076A (ja) 次サリチル酸ビスマスの単位剤形
AU2013267036B2 (en) Non-steroidal anti-inflammatory drug dosing regimen
JP2003277258A (ja) 片頭痛治療剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999949222

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 62197/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2347192

Country of ref document: CA

Ref country code: CA

Ref document number: 2347192

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999949222

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09807453

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999949222

Country of ref document: EP